Organization | Medecins Sans Frontieres

Medecins Sans Frontieres Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4

Founded: Geneva Switzerland (1971)

Organization Overview

First Clinical Trial

2001

NCT00330148

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Alternative names

Epicentre, Mbarara, Uganda | Epicentre MSF | Epicentro, Barranco District, Peru | Medecins Sans Frontieres | Médecins Sans Frontières | Médecins Sans Frontières, Belgium | Médecins Sans Frontières France | Médecins Sans Frontières, France | Medecins sans Frontieres (MSF) | Medecins Sans Frontieres, Netherlands | Medecins sans Frontieres, Operational Centre Amsterdam | Medecins Sans Frontieres, Spain | MSF | MSF (Medecins Sans Frontieres) Belgium

Active Ingredients

Drugs in Phase 4 Trials (25)

amodiaquine (camoquin) (4 trials)

amphotericin b (fungizone) (2 trials)

artesunate (5 trials)

benznidazole (Rochagan) (1 trial)

ciprofloxacin (cipro) (2 trials)

coartem (4 trials)

cobicistat (stribild) (1 trial)

dihydroartemisinin (1 trial)

dolutegravir (tivicay) (2 trials)

efavirenz (sustiva) (2 trials)

elvitegravir (vitekta) (1 trial)

emtricitabine (emtriva) (1 trial)

killed oral cholera vaccine (1 trial)

lamivudine (epivir) (1 trial)

levobupivacaine (chirocaine) (1 trial)

lopinavir (Kaletra) (1 trial)

lumefantrine (Coartem) (4 trials)

mefloquine (lariam) (1 trial)

morphine (1 trial)

piperaquine (1 trial)

quadrivalent groups a, c, y, and w-135 meningococcal vaccine (Menomune-A/C/Y/W-135) (1 trial)

quinine (qualaquin) (1 trial)

ritonavir (Norvir) (1 trial)

tenofovir (viread) (2 trials)

zidovudine (retrovir) (1 trial)

Drugs in Phase 3 Trials (22)

ad26.zebov (Zabdeno) (1 trial)

bedaquiline (sirturo) (6 trials)

brv-pv (Rotasil) (1 trial)

clofazimine (lamprene) (6 trials)

COVID-19 convalescent plasma (1 trial)

delamanid (2 trials)

eflornithine (ornidyl) (3 trials)

ethambutol (myambutol) (1 trial)

isoniazid (nydrazid) (2 trials)

levofloxacin (levaquin) (1 trial)

linezolid (zyvox) (6 trials)

melarsoprol (1 trial)

miltefosine (impavido) (2 trials)

moxifloxacin (avelox) (5 trials)

mva-bn-filo (Mvabea) (1 trial)

nevirapine (viramune) (1 trial)

nifurtimox (Lampit) (3 trials)

pentamidine (pentam) (1 trial)

pretomanid (4 trials)

pyrazinamide (Aldinamide) (2 trials)

rifampin (1 trial)

rvsvdelta-zebov-gp (1 trial)

Drugs in Phase 2 Trials (3)

canakinumab (ilaris) (1 trial)

nitric oxide (inomax) (1 trial)

pyronaridine (1 trial)

Drugs in Other Trials (3)

chlorhexidine (hibitane) (1 trial)

fav-africa (1 trial)

procaine benzylpenicillin (novocaine) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Acquired Immunodeficiency Syndrome (Phase 4)

Bacterial Infections (Phase 3)

Chagas Disease (Phase 4)

Coinfection (Phase 2)

Communicable Diseases (Phase 3)

Extensively Drug-Resistant Tuberculosis (Phase 3)

Gastroenteritis (Phase 3)

Gram-Positive Bacterial Infections (Phase 3)

Hemorrhagic Fever, Ebola (Phase 3)

HIV Infections (Phase 4)

HIV Seropositivity (Phase 3)

Immunologic Deficiency Syndromes (Phase 4)

Infections (Phase 3)

Leg Injuries (Phase 4)

Leishmaniasis (Phase 4)

Leishmaniasis, Cutaneous (Phase 3)

Leishmaniasis, Visceral (Phase 4)

Malaria (Phase 4)

Malaria, Cerebral (Phase 2)

Malaria, Falciparum (Phase 4)

Malnutrition (Phase 4)

Meningitis (Phase 4)

Meningitis, Meningococcal (Phase 4)

Meningococcal Infections (Phase 4)

Mycobacterium Infections (Phase 3)

Recurrence (Phase 3)

Severe Acute Malnutrition (Phase 4)

Trypanosomiasis (Phase 3)

Trypanosomiasis, African (Phase 3)

Tuberculosis (Phase 4)

Tuberculosis, Multidrug-Resistant (Phase 3)

Tuberculosis, Pulmonary (Phase 3)

Virus Diseases (Phase 3)

Wounds and Injuries (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 40
# of Trial APIs: 53